NEFL and Alzheimer disease: Wojdała et al. showed that plasma NF-L, but not serum NF-L, is the most reliable biomarker for AD progression, and their results suggest that measuring plasma NF-L levels may be useful for the early detection of AD, even during the asymptomatic phase.